(19)
(11) EP 1 542 705 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.10.2007 Bulletin 2007/41

(45) Mention of the grant of the patent:
15.08.2007 Bulletin 2007/33

(21) Application number: 03733728.4

(22) Date of filing: 12.06.2003
(51) International Patent Classification (IPC): 
A61K 31/727(2006.01)
A61K 9/20(2006.01)
 A61K 47/44(2006.01)
A61P 7/02(2006.01)
(86) International application number:
PCT/SE2003/000973
(87) International publication number:
WO 2004/000332 (31.12.2003 Gazette 2004/01)

(54)

ANTICOAGULANT COMPOSITION

GERINNUNGSHEMMENDE ZUSAMMENSETZUNG

COMPOSITION ANTICOAGULANTE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 20.06.2002 SE 0201922

(43) Date of publication of application:
22.06.2005 Bulletin 2005/25

(73) Proprietor: DSM IP Assets B.V.
6411 TE Heerlen (NL)

(72) Inventors:
  • HERSLÖF, Bengt
    S-114 21 Stockholm (SE)
  • TINGVALL, Per
    S-738 50 Norberg (SE)

(74) Representative: Chadwick, Mark Craig et al
DSM Intellectual Property Delft Office PP600-0240 P.O. Box 1
2600 MA Delft
2600 MA Delft (NL)


(56) References cited: : 
EP-A2- 0 368 247
WO-A1-02/47663
WO-A1-93/19737
US-A- 5 082 667
 WO-A1-01/91729
WO-A1-92/05771
WO-A1-03/049721
US-A- 5 626 869
   
  • LOHIKANGAS L. ET AL.: 'Relative contribution of phosphatidylcholine and monoglycerine to absorption enhancement of low molecular weight heparin (fragmin) by a new lipid-based drug delivery system in monolayers ...... caco-2 cells and after rectal administration to rabbits' EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES vol. 1, 1994, pages 307 - 312, XP002969238
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).